221 related articles for article (PubMed ID: 24118008)
1. Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients.
Varmavuo V; Rimpiläinen J; Kuitunen H; Nihtinen A; Vasala K; Mikkola M; Kutila A; Lehtonen P; Kuittinen T; Mäntymaa P; Nousiainen T; Kuittinen O; Jantunen E
Transfusion; 2014 May; 54(5):1243-50. PubMed ID: 24118008
[TBL] [Abstract][Full Text] [Related]
2. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.
Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
Transfusion; 2012 Aug; 52(8):1785-91. PubMed ID: 22304442
[TBL] [Abstract][Full Text] [Related]
3. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
4. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.
DiPersio JF; Micallef IN; Stiff PJ; Bolwell BJ; Maziarz RT; Jacobsen E; Nademanee A; McCarty J; Bridger G; Calandra G;
J Clin Oncol; 2009 Oct; 27(28):4767-73. PubMed ID: 19720922
[TBL] [Abstract][Full Text] [Related]
5. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
[TBL] [Abstract][Full Text] [Related]
6. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.
Russell N; Douglas K; Ho AD; Mohty M; Carlson K; Ossenkoppele GJ; Milone G; Pareja MO; Shaheen D; Willemsen A; Whitaker N; Chabannon C
Haematologica; 2013 Feb; 98(2):172-8. PubMed ID: 22983579
[TBL] [Abstract][Full Text] [Related]
7. Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor.
Yuan S; Palmer JM; Tsai NC; Dagis A; Nademanee A; Wang S
Hematol Oncol; 2017 Sep; 35(3):281-287. PubMed ID: 26928577
[TBL] [Abstract][Full Text] [Related]
8. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
9. Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study.
Zhu J; Huang H; Chen H; Zhang X; Li Z; Wu D; Zhou D; Song Y; Hu Y; Liang Y; Ren H; Huang H; Li N; Chen H; Hu J; Li J; Meng R; Wu J; Yu D; Huang X
Transfusion; 2018 Jan; 58(1):81-87. PubMed ID: 29238988
[TBL] [Abstract][Full Text] [Related]
10. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.
Girbl T; Lunzer V; Greil R; Namberger K; Hartmann TN
Transfusion; 2014 Sep; 54(9):2325-35. PubMed ID: 24673458
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
Stewart DA; Smith C; MacFarland R; Calandra G
Biol Blood Marrow Transplant; 2009 Jan; 15(1):39-46. PubMed ID: 19135941
[TBL] [Abstract][Full Text] [Related]
12. Blood graft composition after plerixafor injection in patients with NHL.
Varmavuo V; Mäntymaa P; Nousiainen T; Valonen P; Kuittinen T; Jantunen E
Eur J Haematol; 2012 Aug; 89(2):128-35. PubMed ID: 22536949
[TBL] [Abstract][Full Text] [Related]
13. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
Stiff P; Micallef I; McCarthy P; Magalhaes-Silverman M; Weisdorf D; Territo M; Badel K; Calandra G
Biol Blood Marrow Transplant; 2009 Feb; 15(2):249-56. PubMed ID: 19167685
[TBL] [Abstract][Full Text] [Related]
14. Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.
Bhamidipati PK; Fiala MA; Grossman BJ; DiPersio JF; Stockerl-Goldstein K; Gao F; Uy GL; Westervelt P; Schroeder MA; Cashen AF; Abboud CN; Vij R
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2065-2069. PubMed ID: 28797783
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience.
Jantunen E; Kuittinen T; Mahlamäki E; Pyörälä M; Mäntymaa P; Nousiainen T
Eur J Haematol; 2011 Apr; 86(4):299-304. PubMed ID: 21198864
[TBL] [Abstract][Full Text] [Related]
16. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
17. Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison.
Valtola J; Varmavuo V; Ropponen A; Nihtinen A; Partanen A; Vasala K; Lehtonen P; Penttilä K; Pyörälä M; Kuittinen T; Silvennoinen R; Nousiainen T; Pelkonen J; Mäntymaa P; Jantunen E
Transfusion; 2015 Oct; 55(10):2358-68. PubMed ID: 26018461
[TBL] [Abstract][Full Text] [Related]
18. Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition.
Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
Transfus Apher Sci; 2012 Jun; 46(3):257-62. PubMed ID: 22465758
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience.
Basak GW; Knopinska-Posluszny W; Matuszak M; Kisiel E; Hawrylecka D; Szmigielska-Kaplon A; Urbaniak-Kujda D; Dybko J; Zielinska P; Dabrowska-Iwanicka A; Werkun J; Rzepecki P; Wroblewska W; Wiktor-Jedrzejczak W
Ann Hematol; 2011 May; 90(5):557-68. PubMed ID: 20938660
[TBL] [Abstract][Full Text] [Related]
20. Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma.
Wagstaff AJ
Drugs; 2009; 69(3):319-26. PubMed ID: 19275275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
